AstraZeneca PLC
AZN
$187.03
-$2.72-1.43%
NYSE
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -1.39% | 2.05% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.39% | 2.05% | |||
| Cost of Revenue | -15.68% | 13.54% | |||
| Gross Profit | 2.29% | -0.53% | |||
| SG&A Expenses | -5.47% | 2.35% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -456.60% | 159.55% | |||
| Total Operating Expenses | -9.66% | 5.44% | |||
| Operating Income | 28.65% | -8.60% | |||
| Income Before Tax | 48.88% | -18.96% | |||
| Income Tax Expenses | 177.67% | -57.69% | |||
| Earnings from Continuing Operations | 32.29% | -8.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 66.67% | -50.00% | |||
| Net Income | 32.42% | -8.17% | |||
| EBIT | 28.65% | -8.60% | |||
| EBITDA | 37.90% | -21.07% | |||
| EPS Basic | 32.59% | -8.17% | |||
| Normalized Basic EPS | 30.66% | -8.30% | |||
| EPS Diluted | 32.90% | -8.50% | |||
| Normalized Diluted EPS | 30.66% | -8.42% | |||
| Average Basic Shares Outstanding | -0.13% | 0.00% | |||
| Average Diluted Shares Outstanding | -0.13% | 0.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||